M
Maura Brugiatelli
Researcher at University of Messina
Publications - 112
Citations - 3743
Maura Brugiatelli is an academic researcher from University of Messina. The author has contributed to research in topics: Chronic lymphocytic leukemia & Fludarabine. The author has an hindex of 27, co-authored 112 publications receiving 3355 citations. Previous affiliations of Maura Brugiatelli include University of Turin & University of Genoa.
Papers
More filters
Journal ArticleDOI
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
Andrea Gallamini,Caterina Stelitano,R Calvi,Monica Bellei,Daniele Mattei,Umberto Vitolo,Fortunato Morabito,Maurizio Martelli,Ercole Brusamolino,Emilio Iannitto,Francesco Zaja,Sergio Cortelazzo,Luigi Rigacci,Liliana Devizzi,Giuseppe Todeschini,Gino Santini,Maura Brugiatelli,Massimo Federico +17 more
TL;DR: To assess the prognosis of peripheral T-cell lymphoma unspecified, retrospectively analyzed 385 cases fulfilling the criteria defined by the World Health Organization classification and constructed a new prognostic model that singled out 4 groups at different risk.
Journal ArticleDOI
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Massimo Federico,Stefano Luminari,Emilio Iannitto,Giuseppe Polimeno,Luigi Marcheselli,Antonella Montanini,Antonio La Sala,Francesco Merli,Caterina Stelitano,Samantha Pozzi,Renato Scalone,Nicola Di Renzo,Pellegrino Musto,Luca Baldini,Giulia Cervetti,Francesco Angrilli,Patrizio Mazza,Maura Brugiatelli,Paolo G. Gobbi +18 more
TL;DR: BEACOPP is associated with a significantly improved PFS compared with ABVD, with a predictable higher acute toxicity, and was associated with higher rates of severe infections than ABVD and CEC.
Journal ArticleDOI
R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi
Massimo Federico,Stefano Luminari,Alessandra Dondi,Alessandra Tucci,Umberto Vitolo,Luigi Rigacci,Francesco Di Raimondo,Angelo Michele Carella,Alessandro Pulsoni,Francesco Merli,Luca Arcaini,Francesco Angrilli,Caterina Stelitano,Gianluca Gaidano,Matteo Dell’Olio,Luigi Marcheselli,Vito Franco,Sara Galimberti,Stefano Sacchi,Maura Brugiatelli +19 more
TL;DR: R-CHOP and R-FM were superior to R-CVP in terms of 3-year TTF and PFS in this study and had a better risk-benefit ratio compared with R- FM.
Journal ArticleDOI
Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases
Massimo Federico,Umberto Vitolo,Pier Luigi Zinzani,Teodoro Chisesi,Vera Clò,G. Bellesi,Massimo Magagnoli,Marina Liberati,Carola Boccomini,Pasquale Niscola,Vincenzo Pavone,Antonio Cuneo,Gino Santini,Maura Brugiatelli,Luca Baldini,Luigi Rigacci,Luigi Resegotti +16 more
TL;DR: The prognostic model appears to be very useful in identifying patients with follicular lymphoma at low, intermediate, or high risk.
Journal ArticleDOI
Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients
Pier Luigi Zinzani,Maurizio Martelli,Marilena Bertini,Alessandro M. Gianni,Liliana Devizzi,Massimo Federico,Gerassimos A. Pangalis,Jorg Michels,Emanuele Zucca,Maria Cantonetti,Sergio Cortelazzo,Andrew Wotherspoon,Andrés J.M. Ferreri,Francesco Zaja,Francesco Lauria,Amalia De Renzo,Marina Liberati,Brunangelo Falini,Monica Balzarotti,A. Calderoni,Alfonso Zaccaria,Patrizia Gentilini,Pier Paolo Fattori,Enzo Pavone,Maria K. Angelopoulou,Lapo Alinari,Maura Brugiatelli,Nicola Di Renzo,Francesca Bonifazi,Stefano Pileri,Franco Cavalli +30 more
TL;DR: In patients with PMLBCL with sclerosis, MACOP-B plus radiation therapy may be a better strategy than other treatments; these retrospective data need to be confirmed by prospective studies.